MASSACHUSETTS GENERAL HOSPITAL

Bill Stewart, a 54-year-old New Hampshire man, successfully received a genetically engineered pig kidney transplant on June 14 and no longer requires dialysis after being discharged from Massachusetts General Hospital.

Treeline Biosciences has launched Phase 1 clinical trials for three oncology programs: TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor), and TLN-254 (EZH2 inhibitor) targeting lymphomas and solid tumors.

A custom-built antisense oligonucleotide drug targeting the CHCHD10 gene mutation has slowed ALS progression by more than half in Dr. Rakesh Parekh, marking the first treatment for this specific genetic variant.

Thryv Therapeutics will present compelling preclinical results for THRV-1268, a best-in-class SGK1 inhibitor, at the European Society of Cardiology Congress 2025 in Madrid.

A Phase I/II clinical trial at UMass Chan Medical School demonstrated biochemical correction of GM2 gangliosidosis using dual vector gene therapy with minimal adverse reactions.

The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.

Mass General Brigham has initiated two prospective clinical trials to evaluate Haystack MRD, a highly sensitive circulating tumor DNA test, for guiding postoperative treatment decisions in cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma.

Harvard researchers found that people with Alzheimer's disease have 36% lower lithium levels in their prefrontal cortex compared to those without cognitive decline.

A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.

Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.